Publisher： Adis International
ISSN： 1173-8324
Source： Inpharma, Vol.1, Iss.1641, 2008-01, pp. : 11-11
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Bevacizumab: further evidence of risks in breast cancer patients
Reactions Weekly, Vol. 1, Iss. 1336, 2011-01 ,pp. :
Access to resources
Recommend
Benefit-Risk Assessment of Bevacizumab in the Treatment of Breast Cancer
Drug Safety, Vol. 35, Iss. 1, 2012-01 ,pp. :
Bevacizumab combo keeps breast cancer under control
Inpharma, Vol. 1, Iss. 1540, 2006-01 ,pp. :
Bevacizumab: In First-Line Treatment of Metastatic Breast Cancer
Drugs, Vol. 67, Iss. 12, 2007-01 ,pp. :
Bevacizumab boosts chemotherapy response in breast cancer
Inpharma, Vol. 1, Iss. 1377, 2003-01 ,pp. :